FeesSafety
Pluang+

Helium (HNT) price jumps 11.56% in one hour, hitting $0.3065 with a 24-hour gain of 16.92%.

Market News
08 Nov 2026, 18:07 WIB
Tokenpost
View Source
Bullish
Helium (HNT) price jumps 11.56% in one hour, hitting $0.3065 with a 24-hour gain of 16.92%.

Helium (HNT) experienced a significant price increase of 11.56% within one hour, reaching $0.306534 as of 10:58 a.m. ET on November 8. Over the past 24 hours, HNT's price ranged from $0.257346 to $0.306534, closing near the top of this range with a total gain of 16.92%. The market capitalization of HNT stood at approximately $61.58 million. This price movement highlights growing investor interest in the digital asset, potentially signaling further market activity ahead.

Helium's price surged 11.56% in an hour to $0.306534 on November 8, highlighting notable volatility in the digital asset. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 08, 2026 21:21 WIB: out of 50 major cryptocurrencies, only 7 rose while 42 fell. Among movers, ZIL (Zilliqa) declined 3.90% to Rp30 with a typical hold time of 134 days and Pluang order activity split 45% Sell / 55% Buy; VET (VeChain) dropped 3.75% to Rp93 with 149 days hold time and 53% Sell / 47% Buy; ATOM (Cosmos) fell 3.61% to Rp24,350 with 61 days hold time and 10% Sell / 90% Buy order activity.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
1 hour ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
1 hour ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
1 hour ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
1 hour ago
Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic's $895B AI contract commitments pose major risks to suppliers and Wall Street debt markets.

Anthropic has committed $895.4 billion to future AI infrastructure contracts, heavily impacting suppliers like Broadcom, Alphabet, and Amazon, who are already burning cash to meet these obligations. This massive spending commitment, revealed in Anthr...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App